SU-DIPG-13 NTCC?彌漫型內因性腦橋神經膠細胞瘤細胞株cell line-BioVector NTCC質粒載體菌株細胞蛋白抗體基因保藏中心

價　　格：￥99850
貨　　號：NTCC?_IT41 SU-DIPG-13
產　　地：北京

竭誠為您服務！

BioVector NTCC典型培養物保藏中心: 聯系人：Dr.Xu, Biovector NTCC Inc.; 電話：400-800-2947 工作QQ:1843439339 (微信同號); 郵件：Biovector@163.com; 手機：18901268599; 地址：北京; 已注冊

詳細信息
咨詢記錄(共0條)

The SU-DIPG-13 cell line is a patient-derived cell line used in studies of diffuse intrinsic pontine glioma (DIPG), a fatal pediatric brain tumor:

Stem-like properties
ALDH+ SU-DIPG XIII cells have greater proliferation and neurosphere size than ALDH- cells, suggesting the presence of cancer stem cells in DIPG tumors.
Synergistic activity
The combination of ONC201 and HDAC inhibitors, such as panobinostat or romidepsin, has synergistic activity against SU-DIPG-13 cells.
Transcriptional vulnerabilities
DIPG cells are vulnerable to transcriptional disruption through bromodomain inhibition or CDK7 blockade.
CDK7 inhibition
THZ1, a CDK7 inhibitor, can reduce the growth of DIPG xenografts in vivo and increase median survival in mice.

DIPG is the leading cause of brain tumor-related death in children. The standard treatment is radiation alone, as complete resection is not possible and conventional chemotherapy is ineffective.

Cell pictures: